[go: up one dir, main page]

CL2019002446A1 - Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas. - Google Patents

Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas.

Info

Publication number
CL2019002446A1
CL2019002446A1 CL2019002446A CL2019002446A CL2019002446A1 CL 2019002446 A1 CL2019002446 A1 CL 2019002446A1 CL 2019002446 A CL2019002446 A CL 2019002446A CL 2019002446 A CL2019002446 A CL 2019002446A CL 2019002446 A1 CL2019002446 A1 CL 2019002446A1
Authority
CL
Chile
Prior art keywords
dropropizine
ambroxol
combination
syrup
tablets
Prior art date
Application number
CL2019002446A
Other languages
English (en)
Inventor
Vázquez Jorge Luis Espino
Original Assignee
Productos Farm S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Productos Farm S A De C V filed Critical Productos Farm S A De C V
Publication of CL2019002446A1 publication Critical patent/CL2019002446A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMBINACIÓN FARMACÉUTICA DE AMBROXOL O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y DROPROPIZINA. ASIMISMO, SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA, PREFERENTEMENTE EN UNA FORMA DE ADMINISTRACIÓN ORAL, QUE CONTIENE DICHOS INGREDIENTES ACTIVOS, JUNTO CON UNO O MÁS ADITIVOS FARMACÉUTICAMENTE ACEPTABLES. LA INVENCIÓN TAMBIÉN SE REFIERE A LOS PROCESOS DE PREPARACIÓN Y LOS PROCESOS DE USO DE LA COMBINACIÓN FARMACÉUTICA O LA COMPOSICIÓN FARMACÉUTICA DE LA PRESENTE INVENCIÓN.
CL2019002446A 2017-11-16 2019-08-26 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas. CL2019002446A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2017014725A MX2017014725A (es) 2017-11-16 2017-11-16 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.

Publications (1)

Publication Number Publication Date
CL2019002446A1 true CL2019002446A1 (es) 2019-12-13

Family

ID=66538528

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002446A CL2019002446A1 (es) 2017-11-16 2019-08-26 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas.

Country Status (9)

Country Link
US (2) US20210128496A1 (es)
CL (1) CL2019002446A1 (es)
CO (1) CO2019013645A2 (es)
CR (1) CR20190401A (es)
DO (1) DOP2019000233A (es)
MX (1) MX2017014725A (es)
NI (1) NI201900084A (es)
PE (1) PE20191820A1 (es)
WO (1) WO2019097309A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203721B (it) * 1983-12-29 1989-02-23 Dompe Farmaceutici Spa Composti otticamente attivi ad attivita' antitosse e sedativa centrale,procedimento per la preparazione e composizioni che li contengono
DE19933148A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette
KR101915056B1 (ko) * 2012-04-10 2018-11-07 한미약품 주식회사 암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법

Also Published As

Publication number Publication date
NI201900084A (es) 2020-04-02
US20240082176A1 (en) 2024-03-14
PE20191820A1 (es) 2019-12-27
CO2019013645A2 (es) 2020-01-17
CR20190401A (es) 2019-11-18
DOP2019000233A (es) 2019-12-15
MX2017014725A (es) 2019-05-17
WO2019097309A1 (es) 2019-05-23
US20210128496A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
MX2018014184A (es) Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
CL2019002446A1 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas.
CO2018013792A2 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo
MX2015009681A (es) Un medicamento combinado que comprende finilefrina y paracetamol.
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
AR115724A1 (es) Composición farmacéutica que contiene un péptido
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
MX372644B (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
UY35324A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
EA202092800A1 (ru) Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом
CO2020006701A2 (es) Composiciones farmacéuticas orales de lorazepam resistentes al alcohol
MX2015009504A (es) Composicion farmaceutica de desloratadina para ser administrada por via oral, para el tratamiento de enfermedades relacionadas con la histamina.
UA113237U (uk) Фармацевтична комбінація ацеклофенаку і снодійного або заспокійливого компонента
UA109243U (uk) Тверда лікарська форма, що містить інгібітор віл протеази
GT201500333A (es) Composición farmacéutica sinergística de dos analgésicos con distinto perfil famacocinético
CL2015003409A1 (es) Composición farmacéutica sinergística de dos analgésicos con distinto perfil farmacocinético